Name of journal: World Journal of Gastroenterology

Manuscript NO: 73077

Title: Radiomics Signature: A Potential Biomarker for β-Arrestin1 Phosphorylation Prediction in Hepatocellular Carcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 00505584

Position: Editorial Board

Academic degree: FACS, MD

Professional title: Full Professor, Professor, Surgical Oncologist

Reviewer’s Country/Territory: France

Author’s Country/Territory: China

Manuscript submission date: 2021-11-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-11-09 13:18

Reviewer performed review: 2021-11-12 14:11

Review time: 3 Days

### Scientific quality

- [Y] Grade A: Excellent
- [ ] Grade B: Very good
- [ ] Grade C: Good
- [ ] Grade D: Fair
- [ ] Grade E: Do not publish

### Language quality

- [Y] Grade A: Priority publishing
- [ ] Grade B: Minor language polishing
- [ ] Grade C: A great deal of language polishing
- [ ] Grade D: Rejection

### Conclusion

- [ ] Accept (High priority)
- [ ] Accept (General priority)
- [Y] Minor revision
- [ ] Major revision
- [ ] Rejection

### Re-review

- [Y] Yes
- [ ] No
SPECIFIC COMMENTS TO AUTHORS
**Name of journal:** World Journal of Gastroenterology  

**Manuscript NO:** 73077  

**Title:** Radiomics Signature: A Potential Biomarker for β-Arrestin1 Phosphorylation Prediction in Hepatocellular Carcinoma  

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed  

**Peer-review model:** Single blind  

**Reviewer’s code:** 05610821  

**Position:** Peer Reviewer  

**Academic degree:** MD  

**Professional title:** Surgeon, Surgical Oncologist  

**Reviewer’s Country/Territory:** Italy  

**Author’s Country/Territory:** China  

**Manuscript submission date:** 2021-11-09  

**Reviewer chosen by:** AI Technique  

**Reviewer accepted review:** 2021-12-09 10:03  

**Reviewer performed review:** 2021-12-16 12:41  

**Review time:** 7 Days and 2 Hours  

| Scientific quality | [ ] Grade A: Excellent | [ ] Grade B: Very good | [ Y] Grade C: Good | [ ] Grade D: Fair | [ ] Grade E: Do not publish |  
| Language quality   | [ ] Grade A: Priority publishing | [ Y] Grade B: Minor language polishing | [ ] Grade C: A great deal of language polishing | [ ] Grade D: Rejection |  

**Conclusion**  

| [ ] Accept (High priority) | [ ] Accept (General priority) | [ ] Minor revision | [ Y] Major revision | [ ] Rejection |  

**Re-review**  

[ Y] Yes  
[ ] No
SPECIFIC COMMENTS TO AUTHORS
Feng C et al provided an interesting retrospective study on the role of radiomics as a marker of β-Arrestin1 Phosphorylation in HCC. The manuscript is well written and the reading enjoyable. I do have a concern regarding the methodology of the study and the selection of patients. The authors included only patients undergoing therapy with sorafenib as an adjuvant therapy after hepatic resection, and tested the CRR model not only for the prediction of β-Arrestin1 Phosphorylation but also for the prediction of overall survival. This is something the model was not built for (and less interesting, as the prognosis is related to the presence to β-Arrestin1 Phosphorylation that can be assessed on the specimen, making a preoperative model is useless in this setting).